<DOC>
	<DOCNO>NCT01996683</DOCNO>
	<brief_summary>safety efficacy different iron chelation therapy transfusion dependent beta-thalaasemia patient low serum ferritin continue regular transfusion regimen .</brief_summary>
	<brief_title>Efficacy Safety Efficacy Safety Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin ( &lt; 500 ng/ml )</brief_title>
	<detailed_description>Treatment transfusional iron overload TM patient low serum ferritin ( continued decrease serum ferritin ) even reduction chelation dose .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>â€¢ Subjects low transfusional iron overload secondary thalassemia major show downwardtrend SF last 6 month ( 2 reading need ) . Thalassemia major patient SF equal less 500 reduction chelation dose . Patients different type chelation monotherapy include The subject must also level understand willingness cooperate confinement procedure describe consent form schedule study site . In addition , he/she must able provide voluntary write informed assent consent form . subject HIV positive active HCV . A history serious immunologic hypersensitivity medication anaphylaxis angioedema . Participation previous investigational drug study within 30 day precede screening . A woman childbearing potential must negative serum pregnancy test screening . She must use medically acceptable form birth control study month afterwards pregnant breastfeeding . An inability adhere designate procedure restriction protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>B-thalassemia</keyword>
	<keyword>ferritin</keyword>
</DOC>